Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19

Abstract

: This manuscript is a meta-analysis performed according to PRISMA guidelines. It shows that acute respiratory distress syndrome in COVID-19 complicated by airway obstruction with sputum and mucus, as well as cases of asphyxia with blood, serous fluid, pus, or meconium, can sometimes cause hypoxemia because the medical standard does not include intrapulmonary solutions that release oxygen. One promising avenue for finding and developing the necessary drugs may be the physical-chemical repurposing of hydrogen peroxide solution from antiseptics into inhaled and intrapulmonary mucolytics, pyolytics, and oxygen-releasing antihypoxants by replacing the acidic properties of hydrogen peroxide with alkaline properties. The fact is that an alkaline hydrogen peroxide solution liquefies said biological masses through alkaline saponification of lipid and protein-lipid complexes and simultaneously “blasts” the masses through catalase cleavage of hydrogen peroxide into water and oxygen gas, since these masses are rich in catalase. The results of the first experiments show that inhalation and intrapulmonary injections of alkaline hydrogen peroxide solutions can significantly optimize the treatment of suffocation and hypoxemia. Value of the data: 1. Why are these data useful? These data provide a new perspective way for intrapulmonary drugs and new technologies for the emergency increase of blood oxygenation through the lungs in asphyxia with thick sputum, mucus, pus, meconium and blood. 2. Who can benefit from these data? New drug developers, drug manufacturers, medical professionals providing emergency medical care, as well as pulmonologists, physiatrists, obstetricians and gynecologists can benefit from the data presented in this article. 3. How can these data be used/reused for further insights or development of experiments? These data can be used to develop new drugs and new technologies for the treatment of suffocation and hypoxia in the final stage of COVID-19, severe asthma attacks, purulent obstructive bronchitis, blood asphyxia in cancer and wounded lung in intensive care and anesthesiology departments. In addition, these data can be used to modernize expectorant, mucolytic, pyolytic, hemolytic and meconiolytic and expand the arsenal of intrapulmonary drugs.